GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2012

Apogenix Wins €2.3M to Develop Drug for Myelodysplastic Syndrome

  • Apogenix received a €2.3 million (over $2.99 million) German Federal Ministry of Education and Research (BMBF) grant to support continued clinical development of its lead fusion protein candidate, APG101. The latest award means Apogenix has obtained over €8 million (about $10.42 million) in Federal funding in support of its therapeutic programs since 2007.

    The €2.3 million award will be used for the production of clinical material and progression of a biomarker program relating to development of APG101 for the treatment of myelodysplastic syndrome (MDS). The fully human soluble fusion protein is already in Phase II development for the treatment of glioblastoma multiforme (GBM).

    “We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-of-concept in a Phase II trial planned for 2013,” comments Thomas Höger, Ph.D., Apogenix’ CEO and CFO.

    Apogenix is developing protein therapeutics for the treatment of cancer and inflammatory diseases based on either the targeted modulation of apoptosis or on blocking tumor cell invasion. APG101 combines the extracellular domain of the CD95-receptor and the Fc-portion of IgG. In development initially for the treatment of GBM, AOG101 has also undergone Phase I trials for potential applications against graft versus host disease. The firm’s preclinical programs are focused on the development of IL-4-blocking fusion proteins for the treatment of solid tumors. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?